Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Increased bioavailability of oral melatonin after fluvoxamine coadministration
Autore:
Hartter, S; Grozinger, M; Weigmann, H; Roschke, J; Hiemke, C;
Indirizzi:
Univ Mainz, Neurochem Lab, Dept Psychiat, D-55131 Mainz, Germany Univ Mainz Mainz Germany D-55131 , Dept Psychiat, D-55131 Mainz, Germany
Titolo Testata:
CLINICAL PHARMACOLOGY & THERAPEUTICS
fascicolo: 1, volume: 67, anno: 2000,
pagine: 1 - 6
SICI:
0009-9236(200001)67:1<1:IBOOMA>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMA MELATONIN; SECRETION; 6-HYDROXYMELATONIN; INHIBITOR; SEROTONIN; CANCER; CYP2D6; HUMANS; CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Hartter, S Univ Mainz, Neurochem Lab, Dept Psychiat, Untere Zahlbacherstr 8, D-55131 Mainz, Germany Univ Mainz Untere Zahlbacherstr 8 Mainz Germany D-55131 ermany
Citazione:
S. Hartter et al., "Increased bioavailability of oral melatonin after fluvoxamine coadministration", CLIN PHARM, 67(1), 2000, pp. 1-6

Abstract

Background: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to elevate melatonin serum concentrations. It has not been clear whether these effects might be attributed to an increased melatonin production or to an decreased elimination of melatonin, The latter hypothesis was tested by this study. Methods: Five healthy male volunteers (one CYP2D6 poor metabolizer) received 5 mg melatonin either with or without coadministration of 50 mg fluvoxamine, Serum concentrations of melatonin and fluvoxamine were assessed from 0to 28 hours after melatonin intake. Results: Coadministration of fluvoxamine, on average, led to an 17-fold higher (P < .05) area under concentration-time curve (AUC) and a 12-fold higher (P < .01) serum peak concentration (C-max) of melatonin. The terminal elimination half-life was not significantly affected. The AUC and C-max of fluvoxamine were about three times higher and the half-life was about two times higher in the poor metabolizer. There was a correlation (r = 0.63; P < .01:) between the melatonin and fluvoxamine serum concentrations. The poor metabolizer was found to have: a more pronounced and longer-lasting effect of fluvoxamine on the pharmacokinetics of melatonin,Conclusion: This study showed an increase in the bioavailability of oral melatonin by coadministration of fluvoxamine. The effects of fluvoxamine on the melatonin serum concentrations in patients with depression might therefore be caused by inhibition of the elimination of melatonin and not attributable to an increased production of melatonin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 06:25:50